doi: 10.1177/0960327184003001041.
Pharmacokinetic considerations of misonidazole in therapeutics
- PMID: 6698564
- DOI: 10.1177/0960327184003001041
Item in Clipboard
Pharmacokinetic considerations of misonidazole in therapeutics
Hum Toxicol.
1984 Feb.
Abstract
The pharmacokinetics of misonidazole have been studies in 6 patients with special emphasis on determination of the peak concentration in plasma and saliva. Frequent sampling was performed over 4 h and a marked variation in absorption half-life (range 4-125 min) and time to peak range (0.5-6.5 h) was found. The optimal timing of irradiation is discussed. In addition to a conventional dose, one of the patients received high dose misonidazole; the pharmacokinetics are compared.
Similar articles
-
The pharmacokinetics of misonidazole in the dog.Eur J Cancer (1965). 1979 Oct;15(10):1233-42. doi: 10.1016/0014-2964(79)90249-4. Eur J Cancer (1965). 1979. PMID: 520395 No abstract available.
-
Desmethylmisonidazole (Ro 05-9963): clinical pharmacokinetics after multiple oral administration.Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):377-9. doi: 10.1016/0360-3016(82)90643-5. Int J Radiat Oncol Biol Phys. 1982. PMID: 7107355
-
The metabolism and pharmacokinetics of the hypoxic cell radiosensitizer and cytotoxic agent, misonidazole, in C3H mice.Radiat Res. 1981 May;86(2):341-57. Radiat Res. 1981. PMID: 7232696 No abstract available.
-
Kinetic aspects of misonidazole and its major metabolite in radiotherapy.Hum Toxicol. 1985 Jul;4(4):425-34. doi: 10.1177/096032718500400409. Hum Toxicol. 1985. PMID: 4018823
-
Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients.Br J Cancer. 1981 Oct;44(4):592-6. doi: 10.1038/bjc.1981.232. Br J Cancer. 1981. PMID: 7295516 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources